TACSTD2 and congenital rubella syndrome: used lipid nanoparticles to deliver Trop2-CAR plasmid DNA (LNP/CAR-Trop2) for in situ CAR-M generation after intravenous administration; Trop2-CAR-Ms selectively target Trop2-overexpressing tumors and promote NK and CD8 T cell proliferation, with peak IL-6 levels ~one-fifth of those seen with conventional CAR-T and no serious CRS events (33).